Atika Capital Management LLC purchased a new position in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,000 shares of the company's stock, valued at approximately $540,000. Atika Capital Management LLC owned about 0.34% of Bright Minds Biosciences as of its most recent SEC filing.
Bright Minds Biosciences Stock Up 1.4 %
Shares of Bright Minds Biosciences stock traded up $0.40 during trading on Friday, reaching $29.16. The company's stock had a trading volume of 5,347 shares, compared to its average volume of 816,643. The business has a 50 day moving average price of $35.99 and a 200-day moving average price of $34.70. Bright Minds Biosciences Inc. has a 12-month low of $0.93 and a 12-month high of $79.02. The company has a market capitalization of $205.40 million, a P/E ratio of -172.23 and a beta of -5.50.
Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24. Research analysts predict that Bright Minds Biosciences Inc. will post -1.24 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have weighed in on DRUG shares. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price objective on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. Cantor Fitzgerald started coverage on shares of Bright Minds Biosciences in a research report on Friday, January 10th. They issued an "overweight" rating on the stock. Finally, Piper Sandler began coverage on shares of Bright Minds Biosciences in a research report on Thursday, January 23rd. They set an "overweight" rating and a $93.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $84.33.
Read Our Latest Stock Report on DRUG
Bright Minds Biosciences Company Profile
(
Free Report)
Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.
See Also
Before you consider Bright Minds Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.
While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
